News

OrganOx Completes Acquisition by Terumo Corporation to Advance the Future of Organ Transplantation

$1.5 billion acquisition strengthens global leadership in organ technology and accelerates progress toward making every organ countOXFORD, England and MADISON,…

2 months ago

CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field…

2 months ago

Biomea Fusion to Present Poster Presentations at ObesityWeek®2025

SAN CARLOS, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity…

2 months ago

T-knife Therapeutics Announces Four Upcoming Data Presentations on PRAME-Targeted TK-6302 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

-- Posters will review product characterization and manufacturing data on T-knife’s lead program, TK-6302, a supercharged PRAME T cell receptor…

2 months ago

ORYZON to Participate in Upcoming Events in November

MADRID, Spain and CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage…

2 months ago

Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025

BRISBANE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to…

2 months ago

UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025

Conference Call and Webcast Scheduled for Thursday, November 6th, 2025, at 10:00 AM ETPRINCETON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE)…

2 months ago

Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5

Once-daily, effective, safe, and well-tolerated ZORYVE cream 0.05% now commercially available for children as young as age 2ZORYVE cream 0.05%…

2 months ago

BioCardia Announces University of Wisconsin Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial

SUNNYVALE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for…

2 months ago

Veru Announces Pricing of $25 Million Public Offering

MIAMI, FL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…

2 months ago